QIAGEN Partners with NVIDIA to Expand AI Drug Discovery
Advertisement
Under the partnership, QIAGEN will integrate NVIDIA accelerated computing and the NVIDIA BioNeMo platform into its QIAGEN Digital Insights (QDI) business.
QIAGEN has partnered with NVIDIA, aimed at strengthening the use of AI in drug discovery and biomedical processes.
Under the partnership, QIAGEN will integrate NVIDIA accelerated computing and the NVIDIA BioNeMo platform into its QIAGEN Digital Insights (QDI) business.
The companies seek to combine QIAGEN’s curated biological and bioinformatics knowledge base with NVIDIA’s AI computing technologies to improve data analysis, biomarker discovery, target identification, and drug development.
The partnership is intended to address the gap in navigating complex biological information data through graph-based AI to help researchers identify relevant biological connections within increasingly large and complex datasets while evaluating the biological relevance and credibility of AI-generated insights.
The collaboration is designed to support practical applications across the drug discovery lifecycle, including target identification and validation, drug repurposing, biomarker discovery, pathway analysis, and hypothesis generation from multi-omics data.
By combining curated biomedical knowledge, graph-based AI, and accelerated computing, QIAGEN aims to help research teams move from complex data to better-informed discovery decisions.
Reportedly, initial pilot programmes will be available to select partners in the pharmaceutical and biotechnology sectors, with a broader rollout planned after validation.
Commenting on the new development, Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN, said, “Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation.”
Based in the Netherlands, QIAGEN Digital Insights is developing a range of new AI-enhanced solutions designed to help life sciences organizations extract more value from complex biological, clinical, and molecular data.
These solutions build on more than 25 years of curated biomedical knowledge, including knowledge bases used by more than 150,000 scientists worldwide and supported by more than 70,000 scientific publications.
As per the company, its knowledge system organises evidence across genes, diseases, pathways, compounds, clinical insights, and more than 30,000 diseases to help researchers assess the scientific relevance of AI-generated findings in drug discovery research.
Stay tuned for more such updates on Digital Health News
